Policy & Regulation
Eloxx Pharmaceuticals publishes Phase 2a exaluren data in nonsense mutation Alport syndrome
19 November 2026 -

Clinical-stage biopharmaceutical company Eloxx Pharmaceuticals Inc (Nasdaq:ELOX) announced on Wednesday the publication of results from its Phase 2a proof-of-mechanism study of exaluren in nonsense mutation Alport syndrome in the Journal of Clinical Investigation (JCI).

In the open-label Phase 2a study, three patients aged 12 to 18 years with autosomal recessive Alport syndrome and a COL4A4 premature termination codon received daily subcutaneous exaluren (0.75 mg/kg) for eight weeks. The primary endpoint was safety and tolerability, while secondary endpoints included pre- and post-treatment kidney biopsy assessments.

Kidney biopsies showed increased collagen IV abundance and partially improved podocyte morphology in all three participants.

Masked machine-learning analysis of electron microscopy images showed foot process width reductions of 46%, 14% and 16%. Exploratory analysis showed increased filtration slit density in all participants; mean density increased by 50%, reaching more than 80% of healthy control values.

Eloxx noted that changes in proteinuria were inconsistent, and interpretation was limited by intra-patient variability and the short treatment duration. Hematuria persisted in all participants.

Exaluren was well tolerated, with no serious adverse events, nephrotoxicity or ototoxicity.

The findings support the ongoing Phase 2b EXACT study.

Exaluren (formerly ELX-02) is an investigational, ribosome-targeting glycoside designed to accumulate in kidney cells and promote readthrough of premature stop codons, but not native stop codons, to enable production of full-length, functional proteins.

Login
Username:

Password: